Delayed
NSE India S.E.
04:10:14 2024-07-12 am EDT
|
5-day change
|
1st Jan Change
|
21.13
INR
|
+4.55%
|
|
+0.81%
|
-8.33%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
21,443
|
21,824
|
5,798
|
6,550
|
4,241
|
1,974
|
Enterprise Value (EV)
1 |
20,241
|
24,060
|
9,916
|
11,656
|
4,730
|
2,330
|
P/E ratio
|
13.5
x
|
12.4
x
|
-46.9
x
|
-1.45
x
|
-0.54
x
|
-1.97
x
|
Yield
|
0.61%
|
0.67%
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.35
x
|
1.07
x
|
0.26
x
|
0.85
x
|
0.65
x
|
1.04
x
|
EV / Revenue
|
1.28
x
|
1.18
x
|
0.45
x
|
1.51
x
|
0.72
x
|
1.23
x
|
EV / EBITDA
|
8.41
x
|
8.32
x
|
9.37
x
|
-11.5
x
|
-417
x
|
-9.34
x
|
EV / FCF
|
465
x
|
43.9
x
|
-7.25
x
|
6.7
x
|
0.8
x
|
0.26
x
|
FCF Yield
|
0.21%
|
2.28%
|
-13.8%
|
14.9%
|
124%
|
389%
|
Price to Book
|
1.8
x
|
1.44
x
|
0.37
x
|
0.58
x
|
2.34
x
|
1.82
x
|
Nbr of stocks (in thousands)
|
131,031
|
146,129
|
146,220
|
145,884
|
146,225
|
146,225
|
Reference price
2 |
163.6
|
149.4
|
39.65
|
44.90
|
29.00
|
13.50
|
Announcement Date
|
5/17/18
|
7/15/19
|
9/3/20
|
7/20/21
|
11/29/22
|
7/17/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
15,872
|
20,390
|
22,129
|
7,740
|
6,552
|
1,891
|
EBITDA
1 |
2,408
|
2,891
|
1,058
|
-1,013
|
-11.33
|
-249.6
|
EBIT
1 |
2,028
|
2,322
|
20.02
|
-1,822
|
-725.3
|
-357.3
|
Operating Margin
|
12.78%
|
11.39%
|
0.09%
|
-23.54%
|
-11.07%
|
-18.9%
|
Earnings before Tax (EBT)
1 |
1,880
|
2,157
|
-129.2
|
-4,388
|
-853.1
|
-452.7
|
Net income
1 |
1,605
|
1,773
|
-123.6
|
-4,534
|
-7,823
|
-1,003
|
Net margin
|
10.11%
|
8.7%
|
-0.56%
|
-58.58%
|
-119.39%
|
-53.03%
|
EPS
2 |
12.15
|
12.09
|
-0.8453
|
-31.01
|
-53.50
|
-6.862
|
Free Cash Flow
1 |
43.49
|
548.4
|
-1,368
|
1,739
|
5,877
|
9,062
|
FCF margin
|
0.27%
|
2.69%
|
-6.18%
|
22.47%
|
89.7%
|
479.32%
|
FCF Conversion (EBITDA)
|
1.81%
|
18.97%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
2.71%
|
30.93%
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
1.000
|
1.000
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/17/18
|
7/15/19
|
9/3/20
|
7/20/21
|
11/29/22
|
7/17/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
2,235
|
4,119
|
5,106
|
489
|
356
|
Net Cash position
1 |
1,202
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
0.7731
x
|
3.893
x
|
-5.039
x
|
-43.18
x
|
-1.427
x
|
Free Cash Flow
1 |
43.5
|
548
|
-1,368
|
1,739
|
5,877
|
9,062
|
ROE (net income / shareholders' equity)
|
14%
|
12.5%
|
-0.7%
|
-33.4%
|
-13.6%
|
-32.5%
|
ROA (Net income/ Total Assets)
|
7.88%
|
6.95%
|
0.05%
|
-5.26%
|
-2.96%
|
-3.09%
|
Assets
1 |
20,355
|
25,512
|
-238,150
|
86,150
|
264,686
|
32,497
|
Book Value Per Share
2 |
91.10
|
104.0
|
108.0
|
76.90
|
12.40
|
7.430
|
Cash Flow per Share
2 |
21.70
|
3.200
|
3.090
|
2.670
|
1.980
|
0.7300
|
Capex
1 |
832
|
1,284
|
1,576
|
31.5
|
312
|
324
|
Capex / Sales
|
5.24%
|
6.3%
|
7.12%
|
0.41%
|
4.76%
|
17.13%
|
Announcement Date
|
5/17/18
|
7/15/19
|
9/3/20
|
7/20/21
|
11/29/22
|
7/17/23
|
|
1st Jan change
|
Capi.
|
---|
| -8.33% | 35.39M | | +23.50% | 47.07B | | +46.96% | 42.06B | | -5.16% | 39.98B | | +36.37% | 33.02B | | -7.79% | 27.9B | | +18.06% | 27.63B | | +47.29% | 14.37B | | +41.91% | 13.45B | | -1.02% | 12.03B |
Other Biotechnology & Medical Research
|